Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
| Revenue (Most Recent Fiscal Year) | $332.07M |
| Net Income (Most Recent Fiscal Year) | $18.25M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 36.76 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 19.06 |
| Pre-Tax Margin (Trailing 12 Months) | -0.64% |
| Net Margin (Trailing 12 Months) | -1.46% |
| Return on Equity (Trailing 12 Months) | 3.41% |
| Return on Assets (Trailing 12 Months) | 2.95% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.02 |
| Inventory Turnover (Trailing 12 Months) | 8.48 |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $0.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.19 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 28.87M |
| Free Float | 26.79M |
| Market Capitalization | $541.36M |
| Average Volume (Last 20 Days) | 0.38M |
| Beta (Past 60 Months) | 1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.60% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |